

## Special Issue

# Engineering Aptamers for Biomedical Applications II

### Message from the Guest Editors

This Special Issue, "Engineering Aptamers for Biomedical Applications II", will mainly focus on the more recent advances in the development of highly stable and specific aptamers suitable as therapeutic and diagnostic agents. The introduction of modifications in the nucleic acids backbone, the expansion of genetic variability in nucleobases, and the generation of enzymes able to catalyze the synthesis of modified aptamers is revealing as invaluable advantage in the design of aptamer ligands in biomedicine. Aptamers obtained with nucleic acid variants exhibit high stability in circulating fluids, target binding affinity, and specificity, thus potentially improving their applicability as therapeutics and/or as diagnostic tools. We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.

### Guest Editors

Dr. Vittorio de Franciscis

Istituto per l'Endocrinologia e Oncologia Sperimentale "G. Salvatore",  
Via Tommaso De Amicis 95 Via S. Pansini 5, 80145 Naples, Italy

Dr. Anna Kichkailo

1. Laboratory for Digital Controlled Drugs and Theranostics, Federal Research Center "Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Science", Krasnoyarsk 660036, Russia  
2. Laboratory for Biomolecular and Medical Technologies, Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk 660022, Russia

### Deadline for manuscript submissions

closed (15 February 2021)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/28663](https://mdpi.com/si/28663)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).